315
Participants
Start Date
April 30, 2015
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
aP booster
"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
TdaP booster
"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
Licensed TdaP booster (Boostrix®)
"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
Site 02, Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent
Lead Sponsor
Novartis
INDUSTRY